Case ID: f-supp-2d_466/html/1266-01.html
Source: Caselaw Access Project
Author: {"author": "GRANADE, Chief Judge.", "license": "Public Domain", "url": "https://static.case.law/"}
Date Created: 2024-08-24T03:29:51.129683

Sven-Peter MANNSFELD, Plaintiff, v. PHENOLCHEMIE, INC., et al., Defendants.
    Civil Action No. 06-0413-CG-C.
    United States District Court, S.D. Alabama, Southern Division.
    Nov. 29, 2006.
    
      George W. Finkbohner, III, David G. Wirtes, Jr., Michael A. Worel, Cunningham, Bounds, Yance, Crowder & Brown, LLC, Victor T. Hudson, II, William W. Watts, III, Hudson and Watts, L.L.P., Mobile, AL, for Plaintiff.
    James C. Johnston, Joseph Michael Druhan, Jr., Johnston Druhan, LLP, Mobile, AL, Frank G. Smith, III, Robert Luckett Lee, Alston & Bird, LLP, Jennifer Brown Moore, Atlanta, GA, for Defendants.
   ORDER

GRANADE, Chief Judge.

This matter is before the court on plaintiffs motion to remand (Doc. 12), defendants’ opposition thereto (Doc. 22), plaintiffs reply (Doc. 29), and defendants’ request for oral argument (Doc. 25). The court finds that a hearing is not necessary for resolution of these issues and, therefore, defendants’ motion for oral argument is denied. The court also finds that défendants have not met their burden of demonstrating federal jurisdiction and that, therefore, the motion to remand is due to be granted.

BACKGROUND

This action was originally filed in the Circuit Court of Mobile County, Alabama. Defendants removed the case to this court alleging federal question jurisdiction exists because the uase involves claims that necessitate the resolution of a substantial question of federal patent law. (Doc. 1). The complaint alleges that in 1996 plaintiff developed a business relationship with defendants’ representatives, during which plaintiff, in confidence, communicated to defendants the nature of plaintiffs novel idea, trade secret and/or other confidential information. (Complaint ¶¶ 9, 13). Degussa AG undertook lab tests and pilot runs which allegedly verified plaintiffs novel idea and plaintiff asserts that he is assignee of any and all rights of Degussa AG in and to the novel idea. (Complaint ¶¶ 15, 16). Defendants allegedly applied for and were issued a patent on plaintiffs novel idea without informing plaintiff of their actions or identifying plaintiff as an inventor. (Complaint ¶¶ 17, 18, 19). The complaint asserts eight causes of action: (1) conversion, (2) fraudulent concealment, (3) unjust enrichment, (4) misappropriation of trade secrets, (5) breach of fiduciary duty, (6) tortious interference with contractual or business relations, (7) breach of implied contract, and (8) injunctive relief.

DISCUSSION

Federal courts are courts of limited jurisdiction; therefore, remand statutes are construed narrowly and jurisdictional uncertainties are resolved in favor of remand. Burns v. Windsor Ins. Co., 31 F.3d 1092, 1095 (11th Cir.1994). In evaluating a motion to remand, the removing party bears the burden of demonstrating federal jurisdiction. Pacheco de Perez v. AT & T Co., 139 F.3d 1368, 1373 (11th Cir.1998). The removing party’s burden is heavy. Burns, supra.

.Defendants contend that federal question jurisdiction exists in this case. According to defendants, although plaintiff frames his claims under state law, the central theme of each of-the claims is that plaintiff was harmed when defendants obtained a patent on plaintiffs “novel idea.” Defendants argue that plaintiffs claims clearly depend on both a determination of the scope of the patent and a determination of inventorship for the patent.

It is a well-settled rule that the plaintiff is the master of his or her complaint. See, e.g., Franklin v. QHG of Gadsden, Inc., 127 F.3d 1024, 1028 (11th Cir.1997); U.S. v. Jones, 125 F.3d 1418, 1428 (11th Cir.1997); and Ariail Drug Co., Inc. v. Recomm Int. Display Ltd., 122 F.3d 930, 934 (11th Cir.1997). Notwithstanding the plaintiffs right to choose his forum, some actions filed in state court may be removed to federal court on the basis of federal question jurisdiction. As the Supreme Court has noted:

Only state-court actions that originally could have been filed in federal court may be removed to federal court by the defendant. Absent diversity of citizenship, federal-question jurisdiction is required. The presence or absence of federal-question jurisdiction is governed by the “well-pleaded complaint rule”, which provides that federal jurisdiction exists only when a federal question is presented on the face of the plaintiffs properly pleaded complaint. See Gully v. First Nat’l Bank, 299 U.S. 109, 112-113, 57 S.Ct. 96, 97-98, 81 L.Ed. 70 (1936). The rule makes the plaintiff the master of the claim; he or she may avoid federal jurisdiction by exclusive reliance on state law.

Caterpillar, Inc. v. Williams, 482 U.S. 386, 392, 107 S.Ct. 2425, 96 L.Ed.2d 318 (1987).

The mere fact that a federal statute or regulation may be implicated and even require some interpretation is not sufficient to create federal jurisdiction. For federal question jurisdiction under § 1338(a), the well-pleaded complaint must establish either that “federal patent law creates the cause of action or that the plaintiffs right to relief necessarily depends on resolution of a substantial question of federal patent law....” Christianson v. Colt Industries Operating Corp., 486 U.S. 800, 809, 108 S.Ct. 2166, 100 L.Ed.2d 811 (1988). As the Second Circuit recently explained:

A case “arises under” federal patent law if “a well-pleaded complaint establishes either that federal patent law creates the cause of action or that the plaintiffs right to relief necessarily depends on resolution of a substantial question of federal patent law, in that patent law is a necessary element of one of the well-pleaded claims.” [Christianson, 486 U.S. at 809, 108 S.Ct. 2166.] This is determined “from what necessarily appears in the plaintiffs statement of his own claim in the bill or declaration, unaided by anything alleged in anticipation or avoidance of defenses which it is thought the defendant may interpose.” Id. (internal quotation marks and citation omitted). “[A] case raising a federal patent-law defense does not, for that reason alone, arise under patent law, even if the defense is anticipated in the plaintiffs complaint, and even if both parties admit that the defense is the only question truly at issue in the case.” Id. (internal quotation marks and citation omitted).
Moreover, even if one theory supporting a claim essentially turns on an issue arising under patent law, as long as there is at least one alternative theory supporting the claim that does not rely on patent law, there is no “arising under” jurisdiction under 28 U.S.C. § 1338. In that case, as the Supreme Court concluded in Christianson: “Since there are reasons completely unrelated to the provisions and purposes of federal patent law why petitioners may or may not be entitled to the relief they seek under their monopolization claim, the claim does not arise under federal patent law.” Id. at 812, 108 S.Ct. 2166 (internal quotation marks, citation, and alterations omitted); see also id. at 810, 108 S.Ct. 2166 (“[A] claim supported by alternative théories in the complaint may not form the basis for § 1338(a) jurisdiction unless patent law is essential to each of those theories.”).

In re Tamoxifen Citrate Antitrust Litigation, 466 F.3d 187, 199 -200 (2nd Cir.2006) (footnote omitted).

Upon review of the claims asserted in this case, the court finds that federal patent law did not create the causes of action and that plaintiffs right to relief does not necessarily depend on resolution of a substantial question of federal patent law. Plaintiff does not allege patent infringement or challenge the patent’s validity or enforceability. Plaintiff also does not seek to have the patent voided or corrected in anyway. Plaintiff cites numerous cases which have concluded that federal question jurisdiction does not exist for claims brought by a putative inventor against one who, in breach of an agreement or other confidential relationship, wrongfully disclosed and misappropriated the plaintiffs invention by obtaining a patent on it. (Doc. 29, pp. 5-6 citing Beeher v. Contoure Laboratories, Inc., 279 U.S. 388, 49 S.Ct. 356, 73 L.Ed. 752 (1929); Uroplasty, Inc. v. Advanced Uroscience, Inc., 239 F.3d 1277 (Fed.Cir.2001); AT & T v. Integrated Network Corp., 972 F.2d 1321 (Fed.Cir.1992); Montecatini Edison S.P.A. v. Ziegler, 486 F.2d 1279 (D.C.Cir.1973); Eckert v. Braun, 155 F.2d 517 (7th Cir.1946); Kleinerman v. Snitzer, 754 F.Supp. 1 (D.Mass.1990); Miller v. Rudolph Wurlitzer Co., 48 F.Supp. 772 (D.N.Y.1942); Plastic & Metal Fabricators, Inc. v. Roy, 163 Conn. 257, 303 A.2d 725 (1972); Edwards v. Gramling Engineering. Corporation, 322 Md. 535, 588 A.2d 793 (1991); Stark v. Advanced Magnetics, Inc., 50 Mass.App.Ct. 226, 736 N.E.2d 434 (2000); Ogontz Controls Co. v. Pirkle, 346 Pa.Super. 253, 499 A.2d 593 (1985)). Although obtaining a patent which allegedly includes plaintiffs trade secret or idea is the method by which defendants allegedly violated plaintiffs rights, plaintiff asserts no rights pursuant to the patent or under patent law. Plaintiff only asserts rights with regard to the trade secret' or idea itself. The patent may be evidence in support of plaintiffs allegations, “but the mere presence of the patent does not create a substantial issue of patent law.” Uroplasty, 239 F.3d at 1280 (citation omitted).

Defendants take issue with the merits of plaintiffs claims. For instance defendants contend that the alleged “novel idea” was not novel or confidential. It is unclear how such a contention could support a finding of federal jurisdiction in this case. The court, in evaluating a motion to remand, generally does not consider the merits of plaintiffs claim. See Pacheco de Perez, 139 F.3d at 1380-81 (Even “[i]n a fraudulent joinder inquiry, federal courts are not to weigh the merits of a plaintiffs claim beyond determining whether it is an arguable one under state law.” citation and internal quotations omitted). Consideration of whether the idea at issue was novel or confidential does not require the resolution of a substantial issue of patent law. Plaintiffs claims require that he show that defendants disclosed or used trade secrets or confidential information or ideas, a burden that can be met without requiring the resolution of a substantial issue of patent law. See. Uroplasty, 239 F.3d at 1280.

CONCLUSION

For the reasons stated above, defendants’ request for oral argument (Doc. 25) is DENIED. Plaintiffs motion to remand (Doc. 12) is GRANTED and this case is hereby REMANDED to the Circuit Court of Mobile County, Alabama.